Pharmacologic Management of Hepatic Encephalopathy.

Khalessi, Ali; Pyrsopoulos, Nikolaos T

Khalessi, Ali; Pyrsopoulos, Nikolaos T.

Afiliación

Khalessi A; Rutgers New Jersey School of Medicine, 185 South Orange Avenue, MSB H-538, Newark, NJ 07103, USA.
Pyrsopoulos NT; Rutgers New Jersey School of Medicine, 185 South Orange Avenue, MSB H-538, Newark, NJ 07103, USA. Electronic address: pyrsopni@njms.rutgers.edu.

Clin Liver Dis ; 28(2): 287-296, 2024 05.

Article en En | MEDLINE | ID: mdl-38548440

ABSTRACT

ABSTRACT

Hepatic encephalopathy is a common cause of morbidity and mortality among patients with decompensated liver cirrhosis. In this article, we review the history, mechanism, and evidence for first-line pharmacologic therapies for hepatic encephalopathy including nonabsorbable disaccharides, antibiotics, and electrolyte management. We also review newer, second-line therapies including polyethylene glycol, albumin, branched-chain amino acids, probiotics and fecal microbiota transplant, zinc, and l-ornithine-l-aspartate.

Asunto(s)

Encefalopatía Hepática; Humanos; Encefalopatía Hepática/tratamiento farmacológico; Lactulosa/uso terapéutico; Antibacterianos/uso terapéutico; Polietilenglicoles/uso terapéutico; Zinc/uso terapéutico; Fármacos Gastrointestinales/uso terapéutico

Palabras clave

Hepatic encephalopathy; Lactulose; Nonabsorbable disaccharides; Rifaximin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encefalopatía Hepática Límite: Humans Idioma: En Revista: Clin Liver Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google